Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Leung MW, Bazelier MT, Souverein PC, Uitdehaag BM, Klungel OH, Leufkens HG, Pajouheshnia R. Mapping the risk of infections in patients with multiple sclerosis: a multi-database study in the United Kingdom clinical practice research datalink GOLD and aurum. Mult Scler. 2022 Oct;28(11):1808-18. doi: 10.1177/13524585221094218.
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Dong OM. Excessive dietary sodium intake and elevated blood pressure: a review of current prevention and management strategies and the emerging role of pharmaconutrigenetics. BMJ Nutr Prev Health. 2018 Sep 19;1(1):7-16. doi: 10.1136/bmjnph-2018-000004
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Maclean EN, Stone IS, Ceelen F, Garcia-Albeniz X, Sommer WH, Petersen SE. Reporting standards in cardiac MRI, CT, and SPECT diagnostic accuracy studies: analysis of the impact of STARD criteria. Eur Heart J Cardiovasc Imaging. 2014 Jun;15(6):691-700. doi: 10.1093/ehjci/jet277
Meads DM, Doward LC, McKenna SP, Fisk J, Twiss J, Eckert B. The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler. 2009 Oct 1;15(10):1228-38. doi: 10.1177/1352458509106714
Miret M, Perez-Gutthann S, Gutierrez LP, Viglietta V, Musch B, Greenberg S. Evaluation of the long-term safety of Cladribine tablets: design of a prospective 8-year safety registry. Poster presented at the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS); 2009. Dusseldorf, Germany. [abstract] Mult Scler. 2009 Sep 8; 15(Issue Suppl_9):S239. doi: 10.1177/1352458509106963
Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Mult Scler. 2009 Sep 1;15(9):1092-102.
Doward LC, McKenna SP, Meads DM, Twiss J, Hagell P, Oprandi N. Psychometric and scaling properties of the patient reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler. 2007 Jun;13(Suppl 2):S219.
Doward LC, Meads DM, Fisk JD, McKenna SP, Eckert BJ. Derivation of a unidimensional scale from the fatigue impact scale. Mult Scler. 2006 Sep;12(Suppl 1):S1-S228.